MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12282-022-01425-2

Медицинская библиотека · Breast cancer (Tokyo, Japan) · 2023

Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).

Futamura Manabu, Ishihara Kazuhiro, Nagao Yasuko, Ogiso Atsuko, Niwa Yoshimi, Nakada Takumi, Kawaguchi Yoshihiro, Ikawa Ai, Kumazawa Iwao, Mori Ryutaro, Kitazawa Mai, Hosono Yoshiki, Kuno Masashi, Kawajiri Mana, Nakakami Akira, Takeuchi Makoto, Morikawa Akemi, Tokumaru Yoshihisa, Katagiri Yasuo, Asano Yoshimasa, Mushika Yoshinori, Shimokawa Toshio, Matsuhasih Nobuhisa

Многоцентровое исследованиеКлиническое исследование II фазыСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Nanoparticle albumin-bound paclitaxel (nab-PTX) is a promising antibody partner for anti-human epidermal growth factor receptor 2 (HER2). We performed neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer (BC) using nab-PTX plus trastuzumab (T-mab) and pertuzumab (P-mab), followed by epirubicin and cyclophosphamide (EC).

METHODS

In this multicenter phase II clinical trial (January 2019-July 2020), patients with stage I (T1c)-IIIB HER2-positive primary BC were treated with four cycles of nab-PTX plus T-mab and P-mab, followed by four cycles of EC. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints were clinical response rate (RR), adverse events (AE), and tumor-infiltrating lymphocytes (TILs) in biopsy samples.

RESULTS

In total, 43 patients were enrolled (mean age, 54 years). Twenty-two patients had HER2, and 21 patients had luminal/HER2-subtypes. The overall pCR rate was 53.5% (23/43, 95% CI: 42.6-64.1%, p = 0.184), whilst the pCR for HER2 was 68.2% (15/22, 95% CI: 45.1-86.1) and 38.1% for luminal/HER2 (8/21, 95% CI: 18.1-61.6%). The RR was 100% [clinical (c) CR:25, partial response (PR): 18]. AEs (≥ G3) included neutropenia (23.3%), leukopenia (7.0%), liver dysfunction (7.0%), and peripheral neuropathy (4.7%) when nab-PTX was administered. EC administration resulted in leukopenia (34.2%), neutropenia (31.6%), and febrile neutropenia (15.8%). The TILs in preoperative biopsy samples were significantly higher in pCR compared to non-pCR samples.

CONCLUSION

Nab-PTX plus T-mab and P-mab induced a high pCR rate in HER2-positive BC, particularly in the HER2-subtype. Given that AEs are acceptable, this regimen is safe and acceptable as NAC for HER2-positive BC.

Для цитирования: Futamura Manabu, Ishihara Kazuhiro, Nagao Yasuko, Ogiso Atsuko, Niwa Yoshimi, Nakada Takumi, Kawaguchi Yoshihiro, Ikawa Ai, Kumazawa Iwao, Mori Ryutaro, Kitazawa Mai, Hosono Yoshiki, Kuno Masashi, Kawajiri Mana, Nakakami Akira, Takeuchi Makoto, Morikawa Akemi, Tokumaru Yoshihisa, Katagiri Yasuo, Asano Yoshimasa, Mushika Yoshinori, Shimokawa Toshio, Matsuhasih Nobuhisa. Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).. Breast cancer (Tokyo, Japan). 2023. DOI: 10.1007/s12282-022-01425-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.